Meeting Banner
Abstract #4655

Mutant huntingtin dosage effect on incidence of high striatal Glutamine in a mouse model of Huntington’s disease – a symptom of liver pathophysiology?

Thomas Mueggler1, Andreas Bruns1, Laurence Ozmen1, Herve Schaffhauser1, Basil Künnecke1, and Markus von Kienlin1

1Roche Pharma Research and Early Development, Hoffmann-La Roche Pharmaceuticals Ltd, Basel, Switzerland

In contrast to transgenic models of Huntington’s disease (HD) newly available knock-in models, such as the HttQ175, recapitulate the heterozygosity present in the clinically observed pathophysiology. Here we report a longitudinal assessment of striatal metabolites using 1H-MRS and volumetry in 30+ brain regions in both male and female HttQ175 mice. Apart from a genotype-specific, progressive neurodegenerative phenotype present in both genders, we discovered an entirely novel feature in mouse models of HD, namely individuals with abnormally high glutamine (Gln) levels, whose incidence increased with mutant Htt gene dosage. In line with emerging data on a widespread peripheral metabolic perturbation in HD, we hypothesize that this excessive Gln is a consequence of disordered hepatic metabolism.

This abstract and the presentation materials are available to members only; a login is required.

Join Here